California commercial-stage biopharma firm Geron Corporation has announced that Dr John “Chip” Scarlett, president, chief executive (CEO) and chairman, will depart the company on March 31, 2025. 12 March 2025
UK-based Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its chief executive (CEO) and member of the board of directors effective immediately. 12 March 2025
Harbour BioMed has appointed Michael Patten as chief strategy officer, responsible for overseeing global corporate development and growth strategy. He will also lead the company's global alliance efforts, focusing on expanding its presence in key markets outside China. 11 March 2025
Privately-held Tenpoint Therapeutics, a UK-headquartered biotech focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, has announced the appointment of Carol Kearney as chief commercial officer (CCO). 11 March 2025
Sernova Biotherapeutics, a regenerative medicine company based in Canada and the USA, has announced the appointment of Pericles (Perry) Calias as chief development officer (CDO) and head of R&D. 11 March 2025
US clinical stage biotech Rapport Therapeutics has announced the appointment of Dr Jeffrey Sevigny as chief medical officer (CMO), effective immediately. 7 March 2025
San Francisco-based 3T Biosciences, an immunotherapy company in the field of solid tumors and other immune-mediated diseases, has announced the promotion of Marvin Gee to chief research officer and the appointment of Barbara Sennino as senior vice president and head of early development. 4 March 2025
The UK government has announced the appointment of Lawrence Tallon as the new chief executive (CEO) of the Medicines and Healthcare products Regulatory Agency (MHRA). 4 March 2025
UK-based specialty drugmaker Kelso Pharma has appointed experienced pharma executive, Giovanni Mauri, as general manager at Velit Biopharma, the Italian-based pharma business that was acquired by Kelso in November 2023. 3 March 2025
Danish pharma major Novo Nordisk has announced the appointment of Sebnem Avsar Tuna as the new general manager (GM) of its UK affiliate. 25 February 2025
Eleva, a German company developing difficult-to-produce biologics based on a breakthrough moss-based platform, has announced the appointment of Martin Bauer as its chief medical officer (CMO). 20 February 2025
Privately-held Ventus Therapeutics, a biopharma with two novel small-molecule programs entering Phase II development for immunology, inflammation, and neurology disorders, has appointed Mona Kotecha as chief medical officer (CMO). 19 February 2025
Barcelona, Spain-based biotech Ona Therapeutics today announced key leadership appointments to support its rapid growth and pipeline advancement. 19 February 2025
Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, has announced the appointments of Lahar Mehta as chief medical officer and Scott Greenberg as chief business officer. 18 February 2025
Germany’s Merck KGaA has appointed three new members to its executive board, which it says is a natural evolution in the company’s leadership as it continues to implement its growth strategy. 18 February 2025
Q32 Bio has announced a corporate restructuring, shifting its focus entirely to the development of its lead pipeline drug, bempikibart, for alopecia areata. 11 February 2025
New Jersey, USA-based clinical-stage biotech Imunon has appointed Dr Douglas Faller as chief medical officer, effective February 18, 2025. 10 February 2025
Israel-based Medison, a creator of a first-of-its-kind unified global commercialization platform that accelerates the launch of breakthrough therapies, has announced two key additions to its global leadership team: Shay Tamari as chief business officer (CBO) and Tali Mirsky as chief legal and compliance officer (CLCO). 19 June 2025
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, effective immediately. 17 June 2025
Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organization (CMO) specializing in sterile manufacture of injectable drug products, has appointed Angelika Rublack as senior business development manager to support its expanding global client base and drive growth across several territories. 13 June 2025
US clinical-stage biotech Oncolytics Biotech today announced the appointment of Jared Kelly as chief executive (CEO) and a member of its board of directors. 11 June 2025
US ophthalmic gene therapy company Beacon Therapeutics, which is focused on restoring the vision of patients with blinding retinal diseases, has appointed Daniel Chung as chief medical officer (CMO). 9 June 2025
France-based SparingVision, a genomic medicine company focused on the treatment of retinal disease, has announced the appointment of Kalliopi ‘Kali’ Stasi, as chief medical officer, effective immediately. 9 June 2025
US cardiorenal-focussed drugmaker Ardelyx announced that Mike Kelliher, formerly executive vice president, corporate development and strategy, has been promoted to chief business officer, and James Brady has joined the company as chief human resources officer. 6 June 2025
Danish dermatology specialist LEO Pharma has appointed Helle Hedegaard Juhl as executive vice president for global people and corporate affairs (GPCA). 4 June 2025
Netherlands-based biotech VectorY Therapeutics, which is developing treatments for neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). 2 June 2025
Swiss biotech iOnctura has appointed Steven Sciuto as chief financial officer and Michelle Tsai as chief operating officer, marking a leadership shift as the company moves deeper into Phase II trials for its lead cancer candidate, roginolisib (IOA-244). 2 June 2025
US biotech Hillstar Bio has appointed Maude Tessier as chief operating officer and Shiva Krupa as vice president of program management, reinforcing its leadership bench ahead of a planned clinical entry for its lead autoimmune program in 2026. 29 May 2025
Swedish biotech Hansa Biopharma is preparing to reduce its headcount by around one-fifth as part of a restructuring plan aimed at sharpening operational focus and reducing costs. 27 May 2025
UK biotech Nucleome Therapeutics has appointed Bhavna Hunjan as chief business officer, a move that strengthens its leadership as it advances its pipeline of antibody therapies for inflammatory diseases. 27 May 2025
USA-based nonprofit CureDuchenne has announced the appointment of Brenda Wong as its new chief medical advisor (CMA), effective January 5, 2026. 22 May 2025